Selective natural κ opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction

Drug News and Perspectives

Volumn 22, Issue 7, 2009, Pages 383-392

  Fichna, Jakub ^a   Schicho, Rudolf ^b   Janecka, Anna ^a   Zjawiony, Jordan K ^c   Storr, Martin ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ADL 10 0101; APPETITE STIMULANT; ASIMADOLINE; BROLAMFETAMINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DYNORPHIN A; FEDOTOZINE; KAPPA OPIATE RECEPTOR; LYSERGIDE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; OPIATE AGONIST; PSYCHEDELIC AGENT; RIMONABANT; SALVINORIN A; SALVINORIN B; UNCLASSIFIED DRUG;

ANTINOCICEPTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; LOW DRUG DOSE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DITERPENES, CLERODANE; GASTROINTESTINAL DISEASES; HUMANS; PSYCHOTROPIC DRUGS; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 72449132032     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.7.1400219     Document Type: Review

References (85)

1. Roth, B.L., Baner, K., Westkaemper, R., et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 2002, 99(18): 11934-11939
2. Valdes, L.J., III, Chang, H.M., Visger, D.C. and Koreeda, M. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett 2001, 3(24): 3935-3937
3. Munro, T.A. and Rizzacasa, M.A. Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A. J Nat Prod 2003, 66(5): 703-705 (Pubitemid 36617902)
4. Lee, D.Y., Ma, Z., Liu-Chen, L.Y., Wang, Y., Chen, Y., Carlezon, W.A., Jr. and Cohen, B. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem 2005, 13(19): 5635-5639 (Pubitemid 41187926)
5. Shirota, O., Nagamatsu, K. and Sekita, S. Neo-clerodane diterpenes from the hallucinogenic sage Salvia divinorum. J Nat Prod 2006, 69(12): 1782-1786 (Pubitemid 46144975)
6. A.K., Munro, T.A., Rizzacasa, M.A. and Robins-Browne, R.M. Divinatorins A-C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum. J Nat Prod 2003, 66(9): 1242-1244
7. Harding, W.W., Tidgewell, K., Schmidt, M. et al. Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett 2005, 7(14): 3017-3020
8. Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H. and Watson, S.J. Anatomy of CNS opioid receptors. Trends Neurosci 1988, 11(7): 308-314 (Pubitemid 18150893)
9. Law, P.Y., Wong, Y.H. and Loh, H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000, 40: 389-430. (Pubitemid 30340688)
10. Vonvoigtlander, P.F., Lahti, R.A. and Ludens, J.H. U-50,488: A selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther 1983, 224(1): 7-12.
11. Dykstra, L.A., Gmerek, D.E., Winger, G. and Woods, J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 1987, 242(2): 413-420
12. Pfeiffer, A., Brantl, V., Herz, A. and Emrich, H.M. Psychotomimesis mediated by kappa opiate receptors. Science 1986, 233(4765): 774-776 (Pubitemid 16016229)
13. Simonin, F., Valverde, O., Smadja, C. et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998, 17(4): 886-897 (Pubitemid 28077643)
14. Shippenberg, T.S. and Rea, W. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-oploid receptor agonists. Pharmacol Biochem Behav 1997, 57(3): 449-455 (Pubitemid 27296756)
15. Chamouard, P., Klein, A., Martin, E., Adloff, M. and Angel, F. Regulatory role of enteric kappa opioid receptors in human colonic motility. Life Sci 1993, 53(14): 1149-1156 (Pubitemid 23259278)
16. De Schepper, H.U., Cremonini, F., Park, M.I. and Camilleri, M. Opioids and the gut: Pharmacology and current clinical experience. Neurogastroenterol Motil 2004, 16(4): 383-94.
17. Chavkin, C., Sud, S., Jin, W. et al. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. J Pharmacol Exp Ther 2004, 308(3): 1197-1203 (Pubitemid 38263998)
18. Wang, Y., Tang, K., Inan, S. et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005, 312(1): 220-230 (Pubitemid 40096472)
19. Toll, L., Berzetei-Gurske, I.P., Polgar, W.E. et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 1998, 178: 440-466
20. Simpson, D.S., Katavic, P.L., Lozama, A. et al. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem 2007, 50(15): 3596-3603 (Pubitemid 47195466)
21. Capasso, R., Borrelli, F., Cascio, M.G. et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: Cross-talk between kappa-opioid and cannabinoid CB1 receptors. Br J Pharmacol 2008, 155(5): 681-689
22. Capasso, R., Borrelli, F., Zjawiony, J. et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice. Neurogastroenterol Motil 2008, 20(2): 142-148
23. Capasso, R., Borrelli, F., Capasso, F., Siebert, D.J., Stewart, D.J., Zjawiony, J.K. and Izzo, A.A. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 2006, 18(1): 69-75.
24. Ansonoff, M.A., Zhang, J., Czyzyk, T. et al. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 2006, 318(2): 641-648 (Pubitemid 44061239)
25. John, T.F., French, L.G. and Erlichman, J.S. The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 2006, 545(2-3): 129-133
26. Harding, W.W., Tidgewell, K., Byrd, N. et al. Neoclerodane diterpenes os a novel scaffold for mu opioid receptor ligands. J Med Chem 2005, 48(15): 4765-4771 (Pubitemid 41033119)
27. McCurdy, C.R., Sufka, K.J., Smith, G.H., Warnick, J.E. and Nieto, M.J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 2006, 83(1): 109-113
28. Carlezon, W.A., Jr., Beguin, C., Dinieri, J.A. et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemlstry in rats. J Pharmacol Exp Ther 2006, 316(1): 440-447 (Pubitemid 41832624)
29. Braida, D., Limonta, V., Pegorini, S., Zani, A., Guerini-Rocco, C., Gori, E. and Sala, M. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl) 2007, 190(4): 441-448
30. Braida, D., Limonta, V., Capurro, V. et al. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 2008, 63(3): 286-292
31. Fantegrossi, W.E., Kugle, K.M., Valdes, L.J., III, Koreeda, M. and Woods, J.H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 2005, 16(8): 627-633
32. Wang, Y., Chen, Y., Xu, W. et al. 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 2008, 324(3): 1073-1083
33. Schmidt, M.D., Schmidt, M.S., Butelman, E.R. et al. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 2005, 58(3): 208-210
34. Rothman, R.B., Murphy, D.L., Xu, H. et al. Salvinorin A: Allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther 2007, 320(2): 801-810 (Pubitemid 46147962)
35. Ehlert, F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988, 33(2): 187-194
36. Butelman, E.R., Harris, T.J. and Kreek, M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 2004, 172(2): 220-224
37. Willmore-Fordham, C.B., Krall, D.M., McCurdy, C.R. and Kinder, D.H. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology 2007, 53(4): 481-486
38. Butelman, E.R., Mandau, M., Tidgewell, K., Prisinzano, T.E., Yuferov, V. and Kreek, M.J. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 2007, 320(1): 300-306 (Pubitemid 46025744)
39. Siebert, D.J. Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum. Ann Bot (Lond) 2004, 93(6): 763-771
40. Hooker, J.M., Xu, Y., Schiffer, W., Shea, C., Carter, P. and Fowler, J.S. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008, 41(3): 1044-1050
41. Valdes, L.J., Hatfield, G.M., Koreeda, M. and Paul, A.G. Studies of Salvia divinorum (Lamiaceae), an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico. Economic Botany 1987, 41(2): 283-291
42. Siebert, D.J. Salvia divinorum and salvinorin A: New pharmacologic findings. J Ethnopharmacol 1994, 43(1): 53-56
43. Gonzalez, D., Riba, J., Bouso, J.C., Gomez-Jarabo, G. and Barbanoj, M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 2006, 85(2): 157-162 (Pubitemid 44468138)
44. Sheffler, D.J. and Roth, B.L. Salvinorin A: The "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003, 24(3): 107-109
45. Glennon, R.A., Titeler, M. and McKenney, J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984, 35(25): 2505-2511 (Pubitemid 15212191)
46. Smith, P.B., Welch, S.P. and Martin, B.R. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994, 268(3): 1381-1387
47. Gray, A.C., Coupar, I.M. and White, P.J. Comparison of opioid receptor distributions in the rat central nervous system. Life Sci 2006, 79(7): 674-685 (Pubitemid 43949408)
48. Peckys, D. and Landwehrmeyer, G.B. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 1999, 88(4): 1093-1135 (Pubitemid 28546992)
49. Porreca, F., Cowan, A., Raffa, R.B. and Tallarida, R.J. Ketazocines and morphine: effects on gastrointestinal transit after central and peripheral administration. Life Sci 1983, 32(15): 1785-1790
50. Ward, S.J. and Takemori, A.E. Relative involvement of receptor subtypes in opioid-induced inhibition of gastrointestinal transit in mice. J Pharmacol Exp Ther 1983, 224(2): 359-363
51. Storr, M.A. and Sharkey, K.A. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007, 7(6): 575-582
52. Pagotto, U., Marsicano, G., Cota, D., Lutz, B. and Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27(1): 73-100. (Pubitemid 43228239)
53. Silva, R.M., Grossman, H.C., Hadjimarkou, M.M., Rossi, G.C., Pasternak, G.W. and Bodnar, R.J. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. J Pharmacol Exp Ther 2002, 301(2): 513-518
54. Di Marzo, V. and Matias, I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8(5): 585-589 (Pubitemid 40594198)
55. Fickel, J., Bagnol, D., Watson, S.J. and Akil, H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res 1997, 46(1-2): 1-8. (Pubitemid 27214349)
56. Sternini, C., Patierno, S., Selmer, I.S. and Kirchgessner, A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004, 16(Suppl. 2): 3-16. (Pubitemid 39468862)
57. Sengupta, J.N., Su, X. and Gebhart, G.F. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996, 111(4): 968-980 (Pubitemid 26327599)
58. Duncan, M., Mouihate, A., Mackie, K. et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008, 295(1): G78-87.
59. Coutts, A.A., Irving, A.J., Mackie, K., Pertwee, R.G. and Anavi-Goffer, S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002, 448(4): 410-422 (Pubitemid 34569188)
60. Kulkarni-Narla, A. and Brown, D.R. Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci Lett 2001, 308(3): 153-156 (Pubitemid 32710147)
61. Burton, M.B. and Gebhart, G.F. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998, 285(2): 707-715
62. Corazziari, E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999, 13(Suppl. A): 71A-5A.
63. Delvaux, M., Louvel, D., Lagier, E., Scherrer, B., Abitbol, J.L. and Frexinos, J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116(1): 38-45. (Pubitemid 29013491)
64. Camilleri, M. Novel pharmacology: Asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008, 20(9): 971-979
65. Szarka, L.A., Camilleri, M., Burton, D. et al. Efficacy of on-demand asimadoline, a peripheral koppa-oploid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007, 5(11): 1268-1275 (Pubitemid 350019057)
66. Delgado-Aros, S., Chial, H.J., Camilleri, M. et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003, 284(4): G558-66. (Pubitemid 36343204)
67. Delgado-Aros, S., Chial, H.J., Cremonini, F. Ferber, I., McKinzie, S., Burton, D.D. and Camilleri, M. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18(5): 507-514 (Pubitemid 37152291)
68. Barber, A., Bartoszyk, G.D., Bender, H.M. et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994, 113(4): 1317-1327 (Pubitemid 24364416)
69. Mangel, A.W., Bornstein, J.D., Hamm, L.R., Buda, J., Wang, J., Irish, W. and Urso, D. Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008, 28(2): 239-249 (Pubitemid 351861967)
70. Gue, M., Junien, J.L. and Bueno, L. The kappa agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 1994, 107(5): 1327-1334 (Pubitemid 24328269)
71. Talley, N.J., Choung, R.S., Camilleri, M., Dierkhising, R.A. and Zinsmeister, A.R. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008, 27(11): 1122-1131 (Pubitemid 351614887)
72. Eisenach, J.C., Carpenter, R. and Curry, R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003, 101(1-2): 89-95. (Pubitemid 36044656)
73. Lembo, A. Peripheral opioids for functional GI disease: A reappraisal. Dig Dis 2006, 24(1-2): 91-98 (Pubitemid 43747934)
74. Massa, F., Marsicano, G., Hermann, H. et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004, 113(8): 1202-1209 (Pubitemid 38544105)
75. Holden, K.G., Tidgewell, K., Marquam, A., Rothman, R.B., Navarro, H. and Prisinzano, T.E. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Exploration of the 1-position. Bioorg Med Chem Lett 2007, 17(22): 6111-6115 (Pubitemid 47559129)
76. Beguin, C., Richards, M.R., Wang, Y. et al. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett 2005, 15(11): 2761-2765
77. Beguin, C., Richards, M.R., Li, J.G. et al. Synthesis and in vitro evaluation of salvinorin A analogues: Effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett 2006, 16(17): 4679-4685
78. Stewart, D.J., Fahmy, H., Roth, B.L., Yan, F. and Zjawiony, J.K. Bioisosteric modification of salvinorin A, a potent and selective kappa-opioid receptor agonist. Arzneimittelforschung 2006, 56(4): 269-275
79. Bikbulatov, R.V., Yan, F., Roth, B.L. and Zjawiony, J.K. Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett 2007, 17(8): 2229-2232 (Pubitemid 46505266)
80. Lee, D.Y., Karnati, V.V., He, M. et al. Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett 2005, 15(16): 3744-3747
81. Tidgewell, K., Groer, C.E., Harding, W.W. et al. Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem 2008, 51(8): 2421-2431 (Pubitemid 351628503)
82. Groer, C.E., Tidgewell, K., Moyer, R.A., Harding, W.W., Rothman, R.B., Prisinzano, T.E. and Bohn L.M. An opioid agonist that does not induce micro-opioid receptor - arrestin interactions or receptor internalization. Mol Pharmacol 2007, 71(2): 549-557 (Pubitemid 46147920)
83. Munro, T.A., Rizzacasa, M.A., Roth, B.L., Toth, B.A. and Yan, F. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem 2005, 48(2): 345-348 (Pubitemid 40139777)
84. Lee, D.Y., He, M., Liu-Chen, L.Y. et al. Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues. Bioorg Med Chem Lett 2006, 16(21): 5498-5502
85. Fichna, J., Schicho, R., Andrews, C.N. et al. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil 2009, Advance publication.